International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Nanoparticle-Based Drug Delivery Systems: A Modern Revolution in Targeted Therapy

[1] Preeti verma, [2]Dr. Peeyush Jain,[3]Ms KM Deepshikakha, [4]Mr. Pankaj Chasta

[1] Student of B. Pharmacy at Mewar University
[2] Dean of Department of Pharmacy, Mewar University
[3, 4] Assistant Professor at Mewar University

ABSTRACT :

Nanoparticle-based drug delivery systems represent a significant advancement in precision medicine and targeted therapy, offering enhanced bioavailability, controlled release, and site-specific action. These nanoscale carriers, including liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, are transforming the landscape of pharmacotherapy, especially in oncology and infectious diseases. By improving therapeutic efficacy while minimizing side effects, nanoparticle technologies provide an innovative solution to the limitations of conventional drug formulations. This review explores various types of nanoparticles, mechanisms of drug targeting, clinical applications, and recent innovations, while also addressing associated challenges and future directions for development.

Keywords : Nanoparticles, drug delivery, liposomes, polymeric nanoparticles, cancer therapy, targeted delivery, controlled release.

1. Introduction

The development of nanoparticle-based drug delivery systems (NDDS) marks a breakthrough in pharmaceutical sciences, offering significant improvements in the efficacy, safety, and specificity of drug treatments【1】. Nanoparticles, typically ranging from 1 to 100 nanometers in size, serve as carriers that encapsulate therapeutic agents and deliver them to targeted tissues or cells【2】.

Conventional drug delivery methods often suffer from systemic toxicity, rapid metabolism, and non-specific distribution, leading to suboptimal therapeutic outcomes. NDDS overcomes these limitations by enhancing drug solubility, bioavailability, and circulation time, thereby enabling precise targeting of pathological sites while sparing healthy tissues【3】.

Particularly in cancer therapy, where cytotoxicity is a major concern, nanoparticles provide a mechanism to concentrate drugs within tumors via passive or active targeting strategies【4】. As a result, the use of nanoparticles in drug delivery has attracted substantial research and clinical interest, spurring innovations across biomedical fields.

2. Types of Nanoparticles in Drug Delivery

Nanoparticles are diverse in structure, composition, and function. Based on the material used and application, they are broadly classified into:

- Liposomes
- Polymeric nanoparticles
- Dendrimers
- Metallic nanoparticles
- Solid lipid nanoparticles
- Carbon-based nanocarriers (e.g., fullerenes, graphene)

Each of these types exhibits unique physicochemical properties, drug loading capacities, and biological behavior.

2.1 Liposomes

Liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core. They are biocompatible, biodegradable, and capable of carrying both hydrophilic and hydrophobic drugs【5】.

Advantages:

- Low toxicity and immunogenicity
- Enhanced penetration into tumor tissues

- Ability to be PEGylated for extended circulation time

Applications:

- Doxil® (pegylated liposomal doxorubicin) is FDA-approved for ovarian cancer and Kaposi's sarcoma【6】.

Mechanism:
Liposomes deliver drugs by fusing with the target cell membrane or through endocytosis, releasing the payload in a controlled manner.

2.2 Polymeric Nanoparticles

Polymeric nanoparticles are composed of natural or synthetic polymers, such as PLGA (poly(lactic-co-glycolic acid)), chitosan, or PEG (polyethylene glycol)【7】. These systems offer excellent control over drug release kinetics and are widely used for encapsulating peptides, proteins, and nucleic acids.

Advantages:

- Controlled and sustained drug release
- Surface modification for active targeting
- Improved drug stability and shelf life

Example:
Abraxane® (albumin-bound paclitaxel nanoparticles) is used for metastatic breast cancer and shows improved tolerability compared to free paclitaxel【8】.

Diagram 1: Liposome and Polymeric Nanoparticle Structure

2.3 Dendrimers

Dendrimers are highly branched, tree-like macromolecules with a central core, inner layers (generations), and terminal functional groups. Their symmetrical architecture and multivalency allow for precise control over size, surface functionality, and drug loading【9】.

Advantages:

- High drug loading capacity
- Controlled drug release
- Surface functionalization for active targeting
- Solubilization of poorly water-soluble drugs

Example:
Poly(amidoamine) (PAMAM) dendrimers have shown potential in delivering anticancer agents like methotrexate and doxorubicin【10】.

Mechanism:
Drugs can be conjugated to dendrimer surfaces, encapsulated in their cavities, or bound via ionic interactions. Their nanoscopic size allows for improved cellular uptake via endocytosis.

2.4 Metallic Nanoparticles

Metallic nanoparticles, particularly gold (AuNPs), silver (AgNPs), and iron oxide nanoparticles, are widely used due to their unique optical, magnetic, and catalytic properties【11】.

Advantages:

- Suitable for imaging, diagnostics, and therapy (theranostics)
- Easy surface modification
- Stable under physiological conditions

Applications:

- Gold nanoparticles conjugated with tumor-targeting ligands for photothermal therapy
- Superparamagnetic iron oxide nanoparticles (SPIONs) used in magnetic drug targeting and MRI imaging【12】

3. Mechanisms of Drug Targeting

Targeted drug delivery aims to direct therapeutic agents specifically to diseased sites, minimizing systemic exposure and side effects. Nanoparticles can exploit both **passive** and **active** targeting mechanisms.

3.1 Passive Targeting

Passive targeting relies on the Enhanced Permeability and Retention (EPR) effect, wherein nanoparticles accumulate in tumor tissues due to leaky vasculature and poor lymphatic drainage【13】.

Key Features:

- Does not require ligand-receptor interactions
- Ideal for solid tumors with dense vasculature
- Nanoparticles ≤200 nm in size are optimal for EPR-based targeting

Limitation:
EPR is less effective in poorly vascularized tumors or in inflamed tissues of non-cancer origins.

3.2 Active Targeting

In active targeting, nanoparticles are functionalized with ligands (e.g., antibodies, peptides, aptamers) that bind to specific receptors overexpressed on target cells【14】.

Examples of Targeting Ligands:

Ligand Type	Target Receptor	Application
Folic Acid	**Folate Receptor**	**Ovarian, breast cancer**
Trastuzumab	**HER2**	**Breast cancer**
RGD peptides	**Integrins**	**Angiogenesis targeting**

Mechanism:
Ligand-receptor interactions trigger endocytosis, allowing intracellular drug release and enhanced specificity

4. Clinical Applications in Cancer Therapy

Nanoparticles have gained significant traction in oncology due to their ability to improve therapeutic index, overcome multidrug resistance, and reduce off-target effects. Many formulations are already approved for clinical use, while others are undergoing extensive trials【15】.

4.1 Approved Nanoparticle Drugs

Drug Name	Nanocarrier Type	Indication	Advantage
Doxil®	**Pegylated liposome**	**Ovarian cancer, Kaposi's sarcoma**	**Reduced cardiotoxicity**
Abraxane®	**Albumin nanoparticles**	**Breast, lung, pancreatic cancers**	**Solvent-free formulation**
Onivyde®	**Liposomal irinotecan**	**Pancreatic cancer**	**Improved pharmacokinetics**

These drugs exemplify the successful integration of nanotechnology in clinical oncology, achieving improved tolerability and patient compliance【16】

4.2 Experimental Therapies and Trials

Numerous clinical trials are exploring nanoparticle-based delivery of siRNA, CRISPR/Cas9, and immunomodulators for targeted gene editing and immunotherapy【17】.

Example:

- BIND-014: A PSMA-targeted polymeric nanoparticle for prostate cancer

- CALAA-01: A cyclodextrin-based nanoparticle for siRNA delivery in solid tumors

Advantages in Clinical Settings:

- Tumor-selective accumulation
- Fewer dosing requirements
- Ability to co-deliver multiple agents

4.3 Personalized Nanomedicine

Advancements in genomics and AI are enabling **precision nanoparticle design**, where carriers are tailored to the patient's tumor biology and pharmacogenetics【18】.

- Predictive biomarkers help select suitable nanoparticle-drug combinations.
- AI-driven models optimize particle size, charge, and ligand configuration for individual patients.

5. Challenges and Limitations

Despite promising results, several barriers hinder the widespread adoption of NDDS.

5.1 Biological Barriers

Barrier	Description	Consequence
Mononuclear Phagocyte System (MPS)	**Uptake by liver and spleen macrophages**	**Premature clearance**
Tumor heterogeneity	**Variable EPR effect across tumor types**	**Reduced targeting efficiency**
Endosomal escape	**Entrapment in lysosomes**	**Incomplete drug release**

To overcome these, surface modifications like PEGylation and pH-sensitive coatings are used【19】.

5.2 Scale-Up and Manufacturing

Translating lab-scale formulations to commercial production requires:

- Reproducibility of size and morphology
- Stability during storage and transport
- Regulatory compliance with Good Manufacturing Practices (GMP)

Cost is also a major concern, especially for complex nanocarriers that require multi-step synthesis.

5.3 Regulatory and Safety Concerns

Due to their complexity, nanoparticles face stringent **regulatory hurdles** and **uncertainties** in long-term safety profiles【20】.

- Lack of standardization in characterization
- Limited predictive in vivo-in vitro correlation (IVIVC)
- Potential for accumulation in non-target organs

Regulatory agencies like FDA and EMA are actively developing guidelines for nanomedicine evaluation.

6. Recent Advances and Future Perspectives

The field of nanoparticle-based drug delivery continues to evolve with cutting-edge innovations that promise to reshape modern medicine.

6.1 Smart and Stimuli-Responsive Nanoparticles

These systems release drugs in response to external or internal stimuli such as:

Stimulus Type	Trigger	Application
pH-sensitive	**Acidic tumor microenvironment**	**Site-specific release**
Temperature-sensitive	**Hyperthermia**	**Thermal-responsive chemotherapy**
Enzyme-sensitive	**Tumor-specific enzymes**	**Matrix-degrading targeted therapy**

Example: pH-responsive polymers like poly(histidine) are being used to release drugs specifically at tumor sites【21】.

6.2 Nanoparticles for Gene and RNA Delivery

Delivery of small interfering RNA (siRNA), microRNA (miRNA), and CRISPR/Cas9 tools is emerging as a transformative area in genetic medicine. Nanoparticles help protect nucleic acids from enzymatic degradation and enhance cellular uptake【22】.

- Lipid nanoparticles (LNPs) were successfully used in COVID-19 mRNA vaccines.
- Similar platforms are now being adapted for **oncogene silencing** and **immune modulation**.

6.3 Theranostic Nanoparticles

Theranostic systems combine diagnostic and therapeutic functions in a single platform. These multifunctional nanoparticles allow real-time tracking of drug delivery and treatment response via imaging (MRI, PET, fluorescence)【23】.

Applications:

- Magnetic nanoparticles for imaging-guided chemotherapy
- Quantum dots for simultaneous tumor imaging and drug delivery

6.4 AI-Driven Nanomedicine Design

Artificial Intelligence (AI) is now assisting in:

- Predicting optimal nanoparticle structures
- Modeling pharmacokinetics and toxicity
- Designing individualized treatment regimens【24】

These computational approaches are revolutionizing how nanoparticles are engineered, tested, and applied in precision medicine.

7. Conclusion

Nanoparticle-based drug delivery systems represent a revolutionary advancement in targeted therapy. Their ability to encapsulate, protect, and deliver a wide range of therapeutics—including small molecules, proteins, and nucleic acids—has opened new horizons in precision medicine. From liposomes and polymeric nanoparticles to stimuli-responsive and theranostic platforms, NDDS offer enhanced bioavailability, reduced systemic toxicity, and tumor-specific targeting.

However, despite their tremendous potential, challenges related to biological barriers, manufacturing, regulatory hurdles, and long-term safety must be systematically addressed. The integration of AI, bioinformatics, and personalized medicine promises to refine nanoparticle design and application, moving toward a future of safer and more effective therapeutics.

Continued interdisciplinary research and global collaboration are vital for translating these innovative platforms from laboratory benches to clinical bedsides, ensuring better health outcomes and revolutionizing modern therapeutics【25】.

REFERENCES :

【1】Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. *Experimental and Molecular Pathology*, 86(3), 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004

【2】 Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: entering the mainstream. *Science*, 303(5665), 1818–1822.

https://doi.org/10.1126/science.1095833
【 3 】 Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology*, 2(12), 751–760. https://doi.org/10.1038/nnano.2007.387
【4】 Maeda, H., et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics. *Journal of Controlled Release*, 65(1-2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
【 5 】 Pattni, B. S., et al. (2015). Liposomal drug delivery systems. *Advanced Drug Delivery Reviews*, 91, 106–118. https://doi.org/10.1016/j.addr.2014.09.012
【6】 Gabizon, A. A., et al. (2003). Clinical studies of liposome-encapsulated doxorubicin. *Journal of Liposome Research*, 13(3-4), 311–318. https://doi.org/10.1081/LPR-120026679
【7】 Kumari, A., et al. (2010). Biodegradable polymeric nanoparticles for drug delivery. *Colloids and Surfaces B: Biointerfaces*, 75(1), 1–18. https://doi.org/10.1016/j.colsurfb.2009.09.001
【8】 Gradishar, W. J., et al. (2005). Albumin-bound paclitaxel versus standard paclitaxel. *Journal of Clinical Oncology*, 23(31), 7794–7803. https://doi.org/10.1200/JCO.2005.03.6134
【9】 Tomalia, D. A., et al. (1990). Dendrimers and dendritic polymers. *Progress in Polymer Science*, 15(2), 109–134. https://doi.org/10.1016/0079-6700(90)90005-W
【10】 Kesharwani, P., et al. (2014). PAMAM dendrimers as promising carriers for drug delivery. *Drug Discovery Today*, 19(9), 491–502. https://doi.org/10.1016/j.drudis.2013.11.024
【 11 】 Pissuwan, D., et al. (2011). Targeted therapy using gold nanoparticles. *Trends in Biotechnology*, 29(12), 624–633. https://doi.org/10.1016/j.tibtech.2011.07.003
【12】 Mahmoudi, M., et al. (2011). Superparamagnetic iron oxide nanoparticles for diagnosis and therapy. *Chemical Reviews*, 111(2), 253–280. https://doi.org/10.1021/cr100190t
【13】 Fang, J., et al. (2011). The EPR effect: Unique features of tumor blood vessels. *Advanced Drug Delivery Reviews*, 63(3), 136–151. https://doi.org/10.1016/j.addr.2010.10.009
【14】 Bertrand, N., et al. (2014). Cancer nanotechnology: The impact of passive and active targeting. *Journal of Controlled Release*, 190, 531–537. https://doi.org/10.1016/j.jconrel.2014.03.031
【15】 Bobo, D., et al. (2016). Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials. *Pharmaceutical Research*, 33(10), 2373–2387. https://doi.org/10.1007/s11095-016-1958-5
【 16 】 Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug. *Journal of Controlled Release*, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
【 17 】 Wang, Y., et al. (2018). Nanoparticle delivery of CRISPR/Cas9 for genome editing. *Science Advances*, 4(12), eaas9651. https://doi.org/10.1126/sciadv.aas9651
【 18 】 Kim, J., et al. (2020). Precision nanomedicine in cancer therapy. *Nature Reviews Drug Discovery*, 19(2), 112–131. https://doi.org/10.1038/s41573-019-0049-7
【 19 】 Salvati, A., et al. (2013). Surface functionalization and MPS clearance. *Nature Nanotechnology*, 8(2), 137–143. https://doi.org/10.1038/nnano.2012.237
【20】 Park, K. (2014). Facing the truth about nanotechnology in drug delivery. *ACS Nano*, 7(9), 7442–7447. https://doi.org/10.1021/nn403727v
【21】 Lee, E. S., et al. (2003). pH-sensitive polymers for tumor targeting. *Journal of Controlled Release*, 90(3), 363–374. https://doi.org/10.1016/S0168-3659(03)00212-7
【22】 Hou, X., et al. (2021). Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials*, 6(12), 1078–1094. https://doi.org/10.1038/s41578-021-00358-0
【23】 Mura, S., et al. (2013). Theranostic nanomedicine for personalized cancer therapy. *Advanced Drug Delivery Reviews*, 65(7), 761–779. https://doi.org/10.1016/j.addr.2013.02.008
【 24 】 Tang, Z., et al. (2021). Artificial intelligence in nanoparticle design. *Advanced Materials*, 33(18), 2007404. https://doi.org/10.1002/adma.202007404
【 25 】 Mitragotri, S., et al. (2014). Overcoming challenges in nanomedicine. *Nature Reviews Drug Discovery*, 13(9), 655–672. https://doi.org/10.1038/nrd4364